Bayer Aktiengesellschaft (FRA:BAYN)
27.05
+0.25 (0.91%)
At close: Aug 15, 2025, 10:00 PM CET
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 10.74B EUR in the quarter ending June 30, 2025, a decrease of -3.63%. This brings the company's revenue in the last twelve months to 46.17B, down -1.99% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
46.17B
Revenue Growth
-1.99%
P/S Ratio
0.58
Revenue / Employee
515.59K
Employees
91,864
Market Cap
26.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Siemens Energy AG | 38.39B |
Rheinmetall AG | 10.67B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Bayer Aktiengesellschaft News
- 19 hours ago - Bayer Aspirin Introduces Aspirina to the U.S. Pain Market - Wallstreet:Online
- 19 hours ago - Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market - Business Wire
- 22 hours ago - LumenHaus Powers Bayer 04 Leverkusen as Official Premium Partner for 2025/26 Season - GlobeNewsWire
- 3 days ago - Why are Indoco Remedies shares up 2% today? Explained - Business Upturn
- 3 days ago - Bayer and Kumquat Biosciences partner to develop cancer treatment - Seeking Alpha
- 3 days ago - Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology - Business Wire
- 3 days ago - Bayer inks $1.3 billion deal with Kumquat Biosciences for cancer drug development - Seeking Alpha
- 3 days ago - Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal - Reuters